In non-diabetic mouse hepatocytes, metformin hydrochloride reduced basal and glucagon-stimulated glucose output and suppressed glucagon-induced G6pc and Pck1 expression. The matched glycinate comparator produced similar inhibition for these endpoints under the reported conditions. [2]
The salt comparison also revealed a model-dependent limit. Both formulations enhanced the insulin-associated AKT phosphorylation response in lean-control hepatocytes, whereas only glycinate significantly enhanced the 10 nM insulin response in db/db hepatocytes. Equivalent insulin sensitization by hydrochloride across these models is therefore not established. [2]
PEN2 binding measured by surface plasmon resonance
Biochemical assay · Purified FLAG-tagged PEN2 immobilized on a CM5 chip; PEN2-2A (F35A/E40A) and reference channel controls [1]
Metformin bound PEN2 in an SPR assay, whereas the PEN2-2A mutant showed little binding response. The reported affinity is assay-specific; it is not an AMPK activation EC50 or enzyme IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.05, 0.78125, 1.5625, 3.125 and 6.25 μM
- Exposure duration
- 150 s analyte flow per run
- Method
- BIAcore T200 SPR at 25 °C; reference-channel subtraction and global 1:1 Langmuir fit
- Vehicle
- PBS
- Reported limits
- No Adooq material or lot-specific characterization was reported for this experiment.
Methods and source locations
Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin
Evidence applies to the reported research material and model; it does not validate an Adooq lot.
Fig. 2f; Extended Data Fig. 6f; Results PEN2 binding paragraph; Methods SPR and Reagents
Metformin–PEN2 binding affinity: SPR; experiments performed in triplicate — Results PEN2 binding paragraph; Fig. 2f; Methods SPR
Binding response of PEN2-2A relative to PEN2: SPR comparison with F35A/E40A mutant; additional WT repeat sensorgrams — Extended Data Fig. 6f and caption
PEN2 dependence of low-dose AMPK signaling in mouse hepatocytes
Cell-based study · Primary mouse hepatocytes, wild-type/control versus Pen2-deficient [1]
At 5 μM for 2 h, metformin increased AMPKα and ACC phosphorylation in control hepatocytes, while the low-dose response was blocked by Pen2 loss. The 500 μM comparison retained signaling in deficient cells, limiting an absolute PEN2 requirement. Intracellular metformin uptake was not significantly altered by Pen2 loss in the associated control.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM; 500 μM high-concentration comparator shown in Fig. 2b
- Exposure duration
- 2 h
- Method
- Immunoblotting for phosphorylated and total AMPKα/ACC with PEN2 control; associated intracellular metformin measurement
- Reported limits
- Fig. 2b does not explicitly specify the dosing vehicle; PBS used in the separate SPR assay is not assigned here. Four repetitions are stated for Fig. 2b, without a stated donor count in that caption.
Methods and source locations
Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin
Evidence applies to the reported research material and model; it does not validate an Adooq lot.
Fig. 2b and caption; Extended Data Fig. 3c,j; Methods Primary hepatocytes and Reagents
AMPKα and ACC phosphorylation after metformin: Total AMPKα and ACC and PEN2 assessed; Fig. 2b performed four times — Fig. 2b and caption
Intracellular metformin in primary hepatocytes by genotype: Intracellular metformin analysis; mean ± s.e.m., n = 4 per genotype; two-sided Student’s t-test — Extended Data Fig. 3j and caption
Hydrochloride and glycinate comparison in non-diabetic mouse hepatocytes
Cell-based study · Primary hepatocytes from non-fasted male C57BL/6 mice, age 8–12 weeks [2]
Both salts reduced glucose output in the mouse assay and suppressed glucagon-induced G6pc and Pck1 mRNA; the authors found no significant difference between salts for these endpoints. These endpoints do not demonstrate that AMPK activation is necessary for glucose suppression.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 or 1 mM for glucose output; 0.5 mM for mRNA
- Exposure duration
- 3 h pretreatment; glucose output after a further 6 or 16 h; mRNA at 6 h
- Method
- Culture-medium glucose normalized to protein; RT-qPCR for G6pc/Pck1
- Co-treatment
- Separate salt-comparison arms, with or without 100 nM glucagon; salts were not combined.
- Reported limits
- Vehicle was not specified in the reviewed methods. Data are mean ± SEM from at least 3 independent experiments performed in duplicate; exact mouse/donor count per panel is not given.
Methods and source locations
Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin hydrochloride comparator
Evidence applies to the reported research material and model; it does not validate an Adooq lot.
Revision manuscript Fig. 1A–B and Results 3.1; Methods 2.1, 2.3, 2.6–2.9; PDF physical pp. 15–21
Basal and glucagon-stimulated glucose output: Glucose oxidase/peroxidase assay; glucose referred to total protein — Fig. 1A, Results 3.1 and Methods 2.6
Glucagon-induced G6pc and Pck1 mRNA: RT-qPCR; 0.5 mM formulation exposure and 100 nM glucagon — Fig. 1B and caption; Results 3.1; Methods 2.7, 2.9
Model-dependent insulin signaling after salt pretreatment
Cell-based study · Primary hepatocytes from male db/+ lean controls and db/db diabetic mice (C57BL/KsJ), age 8–12 weeks [2]
Both formulations enhanced the 10 nM insulin-associated AKT phosphorylation response in lean-control hepatocytes. In db/db hepatocytes, only glycinate significantly enhanced that response beyond insulin alone in the authors’ analysis; the hydrochloride effect should not be generalized as equivalent insulin sensitization in diabetic cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 mM of each salt in separate wells
- Exposure duration
- 3 h low-glucose/serum-free conditioning, then 6 h salt pretreatment; insulin during the final 10 min
- Method
- Phospho-AKT Ser473 immunoblots with α-tubulin loading control
- Co-treatment
- Insulin 1 or 10 nM; matched no-insulin, insulin-only, and individual salt conditions
- Reported limits
- Vehicle not specified. Mean ± SEM of at least 3 independent experiments performed in duplicate; exact donor count per condition not specified. Immunoblot phosphorylation is not a direct AKT catalytic-activity assay.
Methods and source locations
Compound reported in the paper: Metformin hydrochloride; Compound label in the paper: Metformin hydrochloride comparator
Evidence applies to the reported research material and model; it does not validate an Adooq lot.
Revision manuscript Fig. 6A–D and Results 3.6; Methods 2.1–2.3, 2.8–2.9; PDF physical pp. 30–32
Additional enhancement of insulin-induced AKT Ser473 phosphorylation in db/db cells: Immunoblot and densitometry; two-way ANOVA with Bonferroni post-hoc analysis — Fig. 6C–D; Results 3.6
Insulin-associated AKT Ser473 phosphorylation in db/+ cells: Immunoblot and densitometry with α-tubulin loading control — Fig. 6A–B; Results 3.6